Sarepta Therapeutics, Inc.

SRPT Healthcare Biotechnology

Sarepta Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.2 billion, up 15.6% from fiscal 2024.

Revenue
−4.51%
EPS
+46.0%
Free cash flow
+231.8%
Total debt
−17.2%

Quarter to September 2026, against a year earlier

17.71 0.14 +0.80%
Market cap
$1.9B
P/E
0.0×
Fwd P/E
6.3×
Dividend yield
—
F-score
3/9
Altman Z
−0.97
Beneish M
−3.41
Dividend safety
n/a

Sarepta Therapeutics, Inc. (SRPT) Operating margin

Alert me on Operating margin

Sarepta Therapeutics, Inc.'s operating margin over the twelve months to 30 September 2026 was −2.50%, up 29.3 percentage points from fiscal 2025 (−31.8%). Over the past ten years it has ranged from −17,572.6% (fiscal 2015) to 11.5% (fiscal 2024); the current reading is higher than 82% of that period. That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.

Operating margin, annual

Embed this chart

Annual newest first

Period Operating margin Change (points)
FY2025 −31.8% (43.30)
FY2024 11.5% 33.01
FY2023 −21.5% 35.93
FY2022 −57.5% 8.03
FY2021 −65.5% 38.96
FY2020 −104.5% 80.81
FY2019 −185.3% (71.12)
FY2018 −114.2% (3.12)
FY2017 −111.0% 4,809.28
FY2016 −4,920.3% 12,652.24

Quarterly newest first

Period Operating margin Change (points)
Sep 2026 −2.37% (5.68)
Jun 2026 3.31% (45.74)
Mar 2026 49.1% 141.97
Dec 2025 −92.9% (67.03)
43 more quarters

Against its own ten years

Low −17,572.6% High 11.5%
Ten-year median −104.5%
Current reading's percentile 87

Operating margin against peers

What Operating margin is

EBIT Margin tells an investor how much operating profit, before interest and taxes, a company keeps from each unit of revenue.

EBIT ÷ Revenue

The full definition of Operating margin →

More on SRPT